Trial Profile
Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2016
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms STONE
- Sponsors Roche
- 26 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 12 Jan 2015 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.